Neil Kumar, BridgeBio CEO (J.T. MacMillan Photography for Endpoints News)
May 30, 2024 07:17 AM EDT
R&D

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

Katherine Lewin

News Reporter

Bridge­Bio re­leased ad­di­tion­al analy­ses of its Phase 3 study of aco­ramidis in AT­TR-CM on Wednes­day, spot­light­ing the link be­tween serum transthyretin (TTR) lev­els and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times